Drug General Information (ID: DDIZYB8VWL)
Drug Name			Tranylcypromine		Drug Info		Dextroamphetamine		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antidepressants				Cns Stimulants
Structure

Mechanism of Tranylcypromine-Dextroamphetamine Interaction (Severity Level: Major)
Additive hypertensive effects Click to Show/Hide Mechanism Graph
Drug Name		Tranylcypromine				Dextroamphetamine
Mechanism 1		Hypertensive effects				Hypertensive effects
Key Mechanism Factor 1
		Factor Name		Hypertensive effects
		Factor Description		Hypertension is defined as a blood pressure reading above a prescribed limit (130/90 mmHg). Most people with hypertension have no signs or symptoms; others may experience: severe headache, shortness of breath, nosebleeds, severe anxiety, and feeling a tingling sensation in the neck or head.
Mechanism Description		Additive hypertensive effects by the combination of Tranylcypromine and Dextroamphetamine
Increased risk of hyperpyrexia Click to Show/Hide Mechanism Graph
Drug Name		Tranylcypromine				Dextroamphetamine
Mechanism 2		Hyperpyrexia				Hyperpyrexia
Key Mechanism Factor 2
		Factor Name		Hyperpyrexia
		Factor Description		Hyperthermia is an extreme, life-threatening increase in core body temperature. If hyperthermia persists for a long time or worsens, more serious symptoms may occur, such as confusion, headache, constricted pupils, vomiting, diarrhea, and decreased urine output.
Mechanism Description		Increased risk of hyperpyrexia by the combination of Tranylcypromine and Dextroamphetamine

Recommended Action
Management		In general, CNS stimulants should not be used concurrently with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).

References
1	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
2	Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
3	FISCHER E, ORLANDO J, LUDMER RL. INFLUENCIA DE METILANFETAMINA, IPRONIACIDA Y TRANILCIPROMINA SOBRE LA DEPRESI'ON PSICOMOTORA ADRENAL'INICA [EFFECT OF METHYLAMPHETAMINE, IPRONIAZID AND TRANYLCYPROMINE ON ADRENALINE PSYCHOMOTOR DEPRESSION]. Prensa Med Argent. 1964;51:1538-1540. [PMID: 14272082]
4	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
5	De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5. [PMID: 4379192]
6	Elis J, Laurence DR, Mattie H, Prichard BN "Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure." Br Med J 2 (1967): 75-8. [PMID: 6020852]
7	Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62. [PMID: 14197995]
8	Harrison WM, McGrath PJ, Stewart JW, Quitkin F "MAOIs and hypertensive crises: the role of OTC drugs." J Clin Psychiatry 50 (1989): 64-5. [PMID: 2464583]
9	Krisko I, Lewis E, Johnson JE "Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity." Ann Intern Med 70 (1969): 559-64. [PMID: 5775035]
10	Markowitz JS, Patrick KS "Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder." Clin Pharmacokinet 40 (2001): 753-72. [PMID: 11707061]
11	Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7. [PMID: 5655478]
12	Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.
13	Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
14	Product Information. Focalin (dexmethylphenidate). Mikart Inc, Atlanta, GA.
15	Product Information. Ritalin (methylphenidate). Novartis Pharmaceuticals, East Hanover, NJ.
16	Product Information. Strattera (atomoxetine). Lilly, Eli and Company, Indianapolis, IN.
17	Product Information. Vyvanse (lisdexamfetamine). Shire US Inc, Florence, KY.
18	Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M "Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs." Ann N Y Acad Sci 107 (1963): 1005-15. [PMID: 13991689]
19	Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36. [PMID: 2510962]
20	Sjoqvist F "Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances." Proc R Soc Med 58 (1965): 967-78. [PMID: 4952963]
21	Smookler S, Bermudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant." Ann Intern Med 11 (1982): 482-4. [PMID: 7114595]
22	Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5. [PMID: 74715]